Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 19
Opinion
Video
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
Author(s):
A panelist discusses how less frequent treatment administration schedules and simpler delivery requirements of newer gene therapies reduce clinic resource burden by minimizing staff time, equipment usage, and biosafety requirements, allowing for more efficient allocation of health care resources.
- How does the ability to administer treatments less frequently, once every 3 months, reduce the resource expenditure in your clinic (eg, staff time and equipment use, allocating more time to patients who need more intensive care or follow-up)?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics like yours (such as monotherapy, biosafety, no reconstitution or dilution required)?
Related Videos
Related Content
